20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
August 2019 in “Carolina Digital Repository (University of North Carolina at Chapel Hill)” DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.
4 citations
,
January 1970 in “Journal of Bangladesh College of Physicians and Surgeons” Early diagnosis and genetic counseling are crucial for managing adrenoleukodystrophy.
2 citations
,
January 2013 in “International Journal of Dermatology” ALDOA levels drop in hair cells during hair loss.
September 1987 in “International Journal of Dermatology” Cimetidine is not a first-choice treatment for female hair loss, and there's no consistently successful treatment for this condition in men or normal hormone level women.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
April 2025 in “Journal of International Medical Research” Androgenetic alopecia has a minor impact on the quality of life for Jordanian men.
April 2012 in “Informa Healthcare eBooks”
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
October 2012 in “Sax's Dangerous Properties of Industrial Materials”
10 citations
,
August 2011 in “Clinics” The author clarified that Alopecia Areata Incognita (AAI) and diffuse Alopecia Areata (AA) are different conditions and the case discussed was actually AA, not AAI.
January 2004 in “Springer eBooks” January 2002 in “Journal of Clinical Dermatology”
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
April 2025 in “Science Journal of University of Zakho” Inflammatory diets may increase the risk and severity of alopecia areata.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
February 1980 in “PubMed” March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.